Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones

Toru Uchiyama,1,8 Sirirat Takahashi,1,8 Kazuhiko Nakabayashi,2 Kohji Okamura,3 Kaori Edasawa,1 Masafumi Yamada,4 Nobuyuki Watanabe,1 Emi Mochizuki,1 Toru Yasuda,1 Akane Miura,1 Motohiro Kato,5 Daisuke Tomizawa,6 Makoto Otsu,7 Tadashi Ariga,4 and Masafumi Onodera1

1Department of Human Genetics, National Center for Child Health and Development, Tokyo, Japan; 2Department of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan; 3Department of System Biomedicine, National Center for Child Health and Development, Tokyo, Japan; 4Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 5Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Tokyo, Japan; 6Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan; 7Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Kanagawa, Japan

Two patients with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (ADA-SCID) received stem cell-based gene therapy (SCGT) using GCsapM-ADA retroviral vectors without preconditioning in 2003 and 2004. The first patient (Pt1) was treated at 4.7 years old, and the second patient (Pt2), who had previously received T cell gene therapy (TCGT), was treated at 13 years old. More than 10 years after SCGT, T cells showed a higher vector copy number (VCN) than other lineages. Moreover, the VCN increased with differentiation toward memory T and B cells. The distribution of vector-marked cells reflected variable levels of ADA requirements in hematopoietic subpopulations. Although neither patient developed leukemia, clonal expansion of SCGT-derived clones was observed in both patients. The use of retroviral vectors yielded clonal dominance of vector-marked clones irrespective of the lack of leukemic changes. Vector integration sites common to all hematopoietic lineages suggested the engraftment of gene-marked progenitors in Pt1, who showed severe osteoblast (OB) insufficiency compared to Pt2, which might cause a reduction in the stem/progenitor cells in the bone marrow (BM). The impaired BM microenvironment due to metabolic abnormalities may create space for the engraftment of vector-marked cells in ADA-SCID, despite the lack of preconditioning.

INTRODUCTION
Defects in adenosine deaminase (ADA), a crucial enzyme in the purine salvage pathway, result in autosomal recessive severe combined immunodeficiency (SCID).1-3 Stem cell-based gene therapy (SCGT) has been developed as a treatment for patients with primary immunodeficiencies who lack suitable donors for hematopoietic stem cell (HSC) transplantation.3,4 In SCGT trials for ADA-deficient SCID (ADA-SCID) patients, multi-lineage engraftment of transduced cells has been achieved by administering busulfan before infusion, which creates space for the engraftment of manipulated HSCs in the bone marrow (BM). A high degree of immune reconstitution has been observed in treated patients and enabled them to discontinue enzyme replacement therapy (ERT) and immunoglobulin (Ig) replacement.5-10 Two Japanese patients with ADA-SCID were treated with SCGT in 2003 and 2004 without cytoreductive conditioning. Partial and temporal reconstitution of the immune system was observed.11,12 In this study, we analyzed the peripheral blood (PB) and BM of these patients for long-term engraftment of vector-marked cells. The vector distributions reflected the extent of the ADA requirements in hematopoietic subpopulations. Therefore, transplantation without preconditioning may also be effective for vector insertions and provide an adequate BM microenvironment for the long-term engraftment of vector-marked cells in ADA-SCID gene therapy.

RESULTS
Patients and clinical trial protocol
The characteristics of the patients and detailed information about the clinical trials have been reported previously.11,12 Briefly, the first patient (Pt1) was a female and developed clinical symptoms 15 days after birth, and ERT using polyethylene glycol-modified ADA (PEG-ADA) was commenced. SCGT using GCsapM-ADA retroviral vectors was performed at the age of 4.7 years. PEG-ADA was withdrawn, and no cytoreductive therapy was administered before SCGT. The second patient (Pt2) was a male and showed delayed onset as he was affected with severe pneumonia 8 months after birth and started PEG-ADA at 1.5 years old. He received T cell gene therapy (TCGT) with LASN retroviral vectors at 4.5 years old, and

Received 26 May 2020; accepted 7 October 2021; https://doi.org/10.1016/j.omtm.2021.10.003.
8These authors contributed equally
Correspondence: Toru Uchiyama, MD, PhD, Department of Human Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535 Japan.
E-mail: uchiyama-t@ncchd.go.jp
insufficient immune reconstitution resulted in the necessity for SCGT at 13.0 years old. TCGT consisted of repeated infusions of autologous gene-modified T cells with continuous ERT, and SCGT was performed under the same protocol as in Pt1. After more than 10 years, both patients showed partial immune reconstitution. Pt1 suffered from mild viral and bacterial infections in the years following the treatment, and her lymphocyte count remained at 200–300/μL, and then genomic DNA was extracted. The VCN was calculated using droplet digital PCR (ddPCR) with primers and probe against the packaging signal (Ψ; Figure 1A). In Pt1, the VCN in T cells was approximately 0.94 per cell, whereas other cell lineages, including B cells, NK cells, monocytes, and granulocytes, showed a VCN of 0.026–0.39 (Figure 1B). Consistent with previous reports, the exogenous expression of ADA provided a definitive selective advantage to the T cell lineage but not to other lineages. Although Pt1 only received SCGT, Pt2 received TCGT followed by SCGT, and, therefore, we also determined the VCN by tracking the GCsapM-ADA-specific sequence to examine the engraftment of SCGT-derived cells in Pt2 (Figure 1A). Pt2 showed a lower VCN (0.32) of GCsapM-ADA in T cells as compared to Pt1. However, as reported elsewhere (unpublished data), the remainder of the T cells contained the LASN vector used in TCGT, and, therefore, the total VCN calculated on the packaging signals was around 0.7 (Figure 1C). A small population of monocytes showed the integration of GCsapM-ADA, but granulocytes showed no integration of the vector. The lower frequency of GCsapM-ADA in T cells may be a consequence of inhibited T cell differentiation from the SCGT-derived HSC/hematopoietic progenitor cells (HPCs) by the presence of TCGT-derived T cells. However, the small number of integrations into myeloid lineages implied the loss of the common progenitors in Pt2. The BM CD34-positive cells from Pt1 showed a higher VCN (0.021) than that of Pt2 (Figure 1D). Detection of vector-marked cells in all hematopoietic

**Engraftment of gene-corrected cells in the hematopoietic system**

We calculated the vector copy number (VCN) in the hematopoietic subpopulations to investigate the long-term engraftment of gene-corrected cells. PB cells were sorted into CD3+ T cells, CD19+ B cells, CD56+ natural killer (NK) cells, CD14+ monocytes, and CD15+ granulocytes, and then genomic DNA was extracted. The VCN was calculated using droplet digital PCR (ddPCR) with primers and probe against the packaging signal (Ψ; Figure 1A). In Pt1, the VCN in T cells was approximately 0.94 per cell, whereas other cell lineages, including B cells, NK cells, monocytes, and granulocytes, showed a VCN of 0.026–0.39 (Figure 1B). Consistent with previous reports, the exogenous expression of ADA provided a definitive selective advantage to the T cell lineage but not to other lineages. Although Pt1 only received SCGT, Pt2 received TCGT followed by SCGT, and, therefore, we also determined the VCN by tracking the GCsapM-ADA-specific sequence to examine the engraftment of SCGT-derived cells in Pt2 (Figure 1A). Pt2 showed a lower VCN (0.32) of GCsapM-ADA in T cells as compared to Pt1. However, as reported elsewhere (unpublished data), the remainder of the T cells contained the LASN vector used in TCGT, and, therefore, the total VCN calculated on the packaging signals was around 0.7 (Figure 1C). A small population of monocytes showed the integration of GCsapM-ADA, but granulocytes showed no integration of the vector. The lower frequency of GCsapM-ADA in T cells may be a consequence of inhibited T cell differentiation from the SCGT-derived HSC/hematopoietic progenitor cells (HPCs) by the presence of TCGT-derived T cells. However, the small number of integrations into myeloid lineages implied the loss of the common progenitors in Pt2. The BM CD34-positive cells from Pt1 showed a higher VCN (0.021) than that of Pt2 (Figure 1D). Detection of vector-marked cells in all hematopoietic
lineages and a relatively higher VCN in the BM imply that gene-marked HSC/HPC subsets engrafted in Pt1 despite the lack of preconditioning.

**Vector distributions in subdivided subsets of T and B cells**

We further investigated the distribution of the retroviral vectors at differentiation stages of T and B cells. CD3+ T cells from both patients were first sorted into CD4+ T, CD8+ T, CD3+CD56+ NKT, and γδ T cells. Among the CD4+ and CD8+ T cells, recent thymic emigrant T (RTE-T; CD4+CD45RA+CD31+), memory CD4 (CD4+CD45RO+), naive CD8 (CD8+CD45RA+), and memory CD8 (CD8+CD45RO+) cells were separated and analyzed for vector integration. In Pt1, most of the T cell subpopulations showed a VCN > 1 (Figure 2A). RTE-T cells, which are a very early stage of naive CD4+ T cells, showed a slightly lower VCN (0.93). In Pt2, the frequency of GCSapM-ADA increased along with differentiation from naive to memory cells (unpublished data), causing changes in the total VCN (Figure 2B). In the RTE-T and naive CD8+ T subsets, T cells without vector integration were present, implying that these subsets have a lower requirement for ADA. Memory T cells required a high level of ADA supplied by the GCSapM-ADA vector rather than the LASN vector.

We also fractionated CD19+ B cells into CD27+ IgM+ B cells (naive B cells), CD27+IgM+ B cells (IgM memory), and CD27+IgM- B cells (class-switched memory) (Figure 2C). In Pt1, whereas naive B cells showed a much lower value (0.049) than T cells, an increase in total VCN was observed along with differentiation toward class-switched memory cells. Remarkably, in Pt2, vector integration was barely detectable (VCN = 0.0025) in naive B cells; however, class-switched memory B cells showed a significantly increased VCN (0.12). Whereas the presence of ADA did not show any selective advantage in naive B cells, the differentiation and maturation processes required a higher level of ADA activity. Vector distribution in the subdivided populations of T and B cells indicated an increase in ADA activity along with differentiation from naive to memory cells.

**Analysis of vector integration sites (ISs) in the patients**

Neither patient received preconditioning, which exposed the transduced cells to proliferative stress. Therefore, we explored the vector ISs to reveal whether genetic factors related to vector insertion into chromosomes might cause prolonged survival of the specific clones in both patients. We established a capture system targeting the sequence of the vector long terminal repeat (LTR), followed by high-throughput sequencing using next-generation sequencing (NGS). A total of 417 ISs with clonal dominance of specified integration (LOC100130950 and tumor necrosis factor [TNF] receptor-associated protein 1 [TRAP1]) were detected (Figure 3A; Table S1) in Pt1. Vector ISs in Pt2 have been reported elsewhere (unpublished data), and most of the highly frequent ISs except SMARCCI were due to the LASN vector used in TCGT (Table S2). The frequency of each integration was less biased in Pt2 than in Pt1.

**Biological influence of genes proximal to ISs on the engraftment of gene-marked cells**

To assess the potential biological impact of vector integration on engraftment, we classified the genes proximal to the vector ISs into defined biological categories using the gene ontology database. Genes with read numbers of more than 0.1% of all integrations were analyzed to determine whether these were enriched in specific categories, but there were no statistically significant enriched categories in either patient (Figure S2).

We also analyzed the frequencies of the categories containing genes hit by the retroviral vector because the genetic/chromatin state of the cells at transduction could influence the insertion profiles. The genes hit in Pt1 and Pt2, which had multiple reads in NGS, were analyzed for categories relating to immune and hematopoietic systems (Table S3). Pt2 showed a relatively high frequency of genes involved in the immune system, including differentiation and response, compared to Pt1, which might reflect the transduction of peripheral T cells at TCGT. In contrast, Pt1 showed increased frequencies of genes with hematopoietic functions, which may be strongly associated with the engraftment of SCGT-derived cells in the BM (Figure S3).

Some genes with high read numbers were categorized as annotated cancer genes in both patients. In Pt1, almost one-half of the total reads was accounted for by integrations into LOC100130950 (24.4%) and TRAP1 (24.0%). TRAP1 is involved in TNF receptor-mediated signal transduction, and overexpression of TRAP1 decreases the production of reactive oxygen species, which accelerates the proliferation of tumor cells. Pt1 also showed two ISs near GPX1 and RAPIB that have been reported to be oncogenes, with total read frequencies of 3.7% and 1.5%, respectively (Figure 3B). In Pt2, five integrations with total frequencies of more than 1% were observed near or in cancer-related genes (DPD4, TNFAIP3/PERP, MLLT10, EPS8, and SPINT1).

To determine the effect of these integrations on the expansion of the clones, we analyzed three of these genes with high frequencies for their expression levels (Figure 3C). The PB of Pt1 showed increased expression of these genes, and statistically significant enrichment was observed for GPX1 and RAPIB. One integration located approximately 39 kb upstream of the LMO2 gene was also analyzed; however, the expression of LMO2 was not detected (data not shown). In Pt2, one integration located between two cancer-related genes, TNFAIP3 and PERP, yielded increased expression of both genes with statistical significance; however, this integration was due to LASN, indicating integration only in peripheral T cells (Figure S4). Among the SCGT-derived clones with GCSapM-ADA integration, SMARCCI expression was also analyzed, although it has not been categorized as a cancer gene. Despite the high frequency of integration into SMARCCI in the IS analysis, we did not observe an increase in its expression level.
Figure 2. Vector distribution in subdivided subsets of T and B cells
(A) The VCN in T cell subpopulations in Pt1. Sorted subsets including CD4+, CD8+, NKT, and γδ T cells were analyzed for the presence of the Ψ sequence. The VCN was also determined in subpopulations of differentiation stages, such as RTE-T (CD4+CD45RA+CD62L+), memory CD4 (CD4+CD45RA), naive CD8 (CD8+CD45RA+), and memory CD8 (CD8+CD45RO+) cells. (B) The VCN in T cell subpopulations in Pt2. ddPCR analysis of Ψ and GCsapM-ADA-specific sequences was performed. (C) The VCN of Ψ in subsets of B cells, including naive (CD27−IgM+), IgM memory (CD27+IgM+), and class-switched memory (CD27+IgM−) B cells.
Quantification of vector integrations in hematopoietic subpopulations

We then investigated the presence of selected integrations that ranked high in read numbers in various hematopoietic lineages. Based on the sequences obtained via NGS, we designed primers/probes against the boundary between the vector and the genomic sequences and performed IS-specific ddPCR in T cells, B cells, NK cells, monocytes, and granulocytes. Pt1 showed integrations into LOC100130950 and TRAP1 in all lineages and three other integrations in T cell and myeloid-cell lineages (Figure 4A; Table 1). Integration upstream of LMO2 was detected only in T cells, with a copy number of 0.012 per cell. These results suggest the engraftment of a small population of vector-marked HSC/HPCs or less primitive progenitors with the potential for multi-lineage differentiation in Pt1. Quantification revealed that two integrations into LOC100130950 and TRAP1 comprised most of the vector integrations in the T cells. These two integrations also exhibited a slight dominance over other integrations in monocytes and granulocytes but not in B cells and NK cells. In Pt2, the integrations due to LASN were detected only in T cells, and the distribution of GCsapM-ADA integration into SMARCC1 was explored. T cells showed a dominance of integration into SMARCC1, and this also comprised most of the integrations in B cells (Figure 4B).

Whether these vector integrations facilitate the proliferation of clones remains unclear because these genes in the dominant clones (LOC100130950 and TRAP1 in Pt1 and SMARCC1 in Pt2) were not categorized as cancer genes, or their expression levels did not increase. Each integration was analyzed for the distance from the active transcriptional start sites (TSS) of the nearest cellular gene. Unlike the typical pattern of retroviral vector,14 the integrations in both patients showed no tendency to accumulate at TSS of cellular genes (Figure S5). In contrast, three dominant integrations (LOC100130950, AB...
TRAP1, and SMARCC1) were in the active TSS of these genes, which could yield a higher level of vector transcription than other integrations (Figure S6). High ADA expression might facilitate the proliferation in the metabolically active subsets such as T cells, leading to the clonal dominance of these clones.

These results indicate that some factors other than insertional mutagenesis including the expression level of ADA in each clone may affect the clonal distributions of retrovirally transduced clones in ADA-SCID.

**Microenvironment characteristics of the BM**

Pt1 showed multi-lineage engraftment of vector-marked cells with a higher VCN in CD34-positive cells than that in Pt2. Pt1 displayed a severe clinical phenotype, and the accumulation of toxic metabolites might lead to impairment in the BM microenvironment, which may play a role as “auto-conditioning” and yield the engraftment of vector-marked progenitor cells without preconditioning therapy. Osteoblasts (OBs) and osteoclasts (OCs) are crucial components of the HSC niche and maintain stem cell properties, including self-renewal and multi-lineage hematopoiesis.\(^{17-19}\) Receptor activator of nuclear factor-kB ligand (RANKL) is produced by OBs and is required for cross-talk between OBs and OCs. The ratios of RANKL relative to its decoy receptor osteoprotegerin (OPG) were decreased in ADA-SCID patients,\(^ {20}\) and SCGT recovers the microenvironment with an increase in RANKL level. We measured the ratios of RANKL to OPG in the plasma of both patients. Pt1 showed a lower RANKL/OPG ratio than did Pt2, despite the engraftment of gene-corrected cells in the BM, indicating a severe defect in the BM microenvironment in Pt1 compared to Pt2 (Figure 5).

**DISCUSSION**

The patients in this study did not receive busulfan conditioning, and, therefore, full engraftment of gene-corrected cells was not successful. Several factors, including the disease background, influence the complex engraftment pattern of gene-corrected cells. A distribution of gene-marked cells revealed differences in the required levels of ADA in different cell types and at various differentiation stages. T cells are more sensitive to toxic metabolites than other immune cell subpopulations, so ADA activity is higher in T cells than in other cell types.\(^ {21-25}\) Consistently, the patients in this study showed higher VCNs in T cells, indicating an increased need for ADA, than in other hematopoietic cells. Among T cells, homeostatic proliferation is higher in CD8+ T cells than in CD4+ T cells,\(^ {26,27}\) and memory T cells appear to have higher metabolic activity than the naive subset.\(^ {28,29}\) These features were reflected in the VCN pattern in Pt2, who had both transduced and non-transduced cells in the T cell subset. In Pt2, the VCN was higher in CD8+ T cells than in CD4+ T cells and increased along with differentiation from naive to memory subsets, which indicates that vector-derived ADA could metabolize the accumulated deoxyadenosine in memory subsets with frequent divisions.

The low VCNs in B cells, NK cells, and myeloid lineage cells suggest that vector-derived ADA did not confer a survival advantage in these cell types. Previous reports have shown that a selective advantage provided by ADA was observed in naive B cells but not in BM immature B cells.\(^ {30}\) Although our patients showed a low VCN in naive B cells,
the selective advantage of gene-corrected B cells could be observed during their maturation from naive to memory subsets, suggesting increasing levels of nucleic acid metabolism on B cell differentiation.

It has been reported that preferential targets for integration are closely related to the epigenetic state and expression profiles of the cell type at transduction. Thirteen Therefore, the possible engrafment of vector-marked HPC/HSCs may reflect the integration profiles of Pt1 with a relatively high frequency of the ISs in or near genes involved in hematopoietic cell development, differentiation, and proliferation. In contrast, Pt2 possessed TCGT-derived cells in the periphery but showed few engrafments of the clones with multi-lineage differentiation potential. These engrafment patterns might correspond to the integration profiles of Pt2 with a relatively higher frequency of genes related to the immune system but a lower frequency related to the hematopoietic system than Pt1. However, the frequencies of genes with immune functions in Pt2 were lower than that in patients with PB lymphocyte-gene therapy in a previous report. More than 20 years passed since Pt2 received TCGT, so functional T cell clones with integration into immune system-related genes might have been exhausted by the time of our analysis.

Although neither patient developed leukemia in more than 10 years after SCGT, the impact of genetic alterations due to vector integration on the long-term engrafment of vector-marked clones remains unclear. Both patients possessed clones with integrations near cancer-related genes. Pt1 showed the dominant proliferation of two clones, one of which had an integration into a cancer gene, TRAP1, but its expression level was not increased. In Pt2, LASN insertion between TNFAIP3 and PERP caused the increased expression of both genes. Although transduction of peripheral T cells in TCGT did not cause the oncogenic transformation of repopulating cells, this integration might increase the long-term survival of this T cell clone. The integration into SMARCC1 accounted for a large portion of GCsapM-ADA integrations, which indicates the clonal dominance of an SCGT-derived clone, also in Pt2. However, SMARCC1 has not been reported as a cancer gene, and its expression level did not increase. These results suggest that mechanisms other than insertional mutagenesis induced the clonal proliferation of the dominant clones.

The dominant clones (LOC100130950 and TRAP1 in Pt1 and SMARCC1 in Pt2) had GCsapM-ADA integrations in active TSS of cellular genes, which might result in effective transcription of vector-derived ADA. Most of other integrations in both patients, in contrast, were located away from the sites of H3K4me3 modification corresponding to TSS of the cellular genes and might yield a lower vector transcription. The hematopoietic subpopulations showed variable levels of ADA activity, and, therefore, a clone with a higher level of ADA activity could proliferate and dominate over other clones in metabolically active subsets including T cells. In B cells, Pt2 showed a clonal pattern of vector integrations, whereas Pt1 did not. Vector-derived ADA confers a growth advantage in memory B cells but not in naive B cells (Figure 2C), indicating that clonal dominance due to high ADA expression may be observed in memory B cells. Pt2 showed few integrations in naive B cells (VCN = 0.0025), and the possible clonal dominance in the memory subset may result in the clonal expansion of SMARCC1 in the total B cell subset. In contrast, a relatively higher frequency of vector-marked cells in naive B cells (VCN = 0.049) might result in non-dominant proliferations of LOC100130950 and TRAP1 in total B cells of Pt1. In any case, these results suggest that the retroviral transduction of stem/progenitor cells yielded clonal hematopoiesis by clones with strong proliferating potential, which might be the result of various factors, in ADA-SCID.

Accumulation of toxic metabolites causes stem cell defects in ADA-SCID, which could play a role as auto-conditioning and create stem cell niches. Pt2 showed residual ADA activity in hematopoietic cells, and there may be few niches in the BM, leading to lower engrafment of gene-corrected cells than that in Pt1. Toxic substrates may directly inhibit the survival of stem/progenitor cells, like other hematopoietic cells. Additionally, an abnormal environment in the BM may also reduce the number of stem cells. Sauer et al. reported that ADA-SCID patients showed a reduction in the RANKL/OPG ratio, indicating the OB insufficiency and impairment of the HSC niche, and SGCT rescued the microenvironment indicated by an increase in the RANKL/OPG ratio. Pt1 showed a lower RANKL/OPG ratio than did Pt2 despite a higher VCN in the BM, indicating that Pt1 had a severe defect in the BM microenvironment. It remains unclear whether the impaired BM microenvironment could provide a

### Table 1. Integration site-specific droplet digital PCR for the integration of the GCsapM-ADA vector

| Gene            | CD3⁺ T | CD19⁺ B | CD56⁺ NK | Mono    | Gra     |
|-----------------|--------|---------|---------|---------|---------|
| LOC100130950    | 0.3989 | 0.0102  | 0.0007  | 0.0042  | 0.1124  |
| TRAP1           | 0.2978 | 0.0105  | 0.0043  | 0.0052  | 0.0610  |
| ZFAND3          | 0.1072 | 0       | 0       | 0.0014  | 0.0384  |
| USP4            | 0.0344 | 0       | 0       | 0       | 0.0193  |
| DIP2A           | 0.0806 | 0       | 0       | 0.0015  | 0.0097  |
| LMO2            | 0.0119 | 0       | 0       | 0       | 0       |
| Pt1             |        |         |         |         |         |
| Pt2             |        |         |         |         |         |
| SMARCC1         | 0.1137 | 0.0355  | 0.0040  | 0.0024  | 0       |

Pt1, patient 1; Pt2, patient 2; Mono, monocytes; Gra, granulocytes.
*aCopy number was calculated as the number of signals per cell.*
sufficient niche for the gene-corrected cells. However, the reduction in stem cells due to metabolic toxicity could have created space in the BM that facilitated engraftment without preconditioning.

Overall, SCGT without preconditioning led to a complex engraftment pattern of vector-marked cells, which may be affected by nucleotide metabolism in hematopoietic subpopulations and the BM microenvironment in ADA-SCID. The clonal proliferation of vector-integrated clones, although there was no increase in the transcription of cellular genes, implies that other mechanisms of clonal dominance are at play rather than insertional mutagenesis.

MATERIALS AND METHODS

Study approval

All study protocols involving the participation of the patients were approved by the Ethics Committee of the National Center for Child Health and Development. PB and BM samples were obtained from both patients. The patients and their parents provided written, informed consent to comply with standard ethical procedures.

Flow cytometry and fluorescent-activated cell sorting

Mononuclear cells from PB and BM cells were stained with the following antibodies (BioLegend, San Diego, CA, USA): fluorescein isothiocyanate (FITC) anti-CD3, APC anti-CD19, PE anti-CD56, and PerCP-Cy5.5 anti-CD14 for the isolation of T cells (CD3⁺), B cells (CD19⁺), NK cells (CD56⁺), and monocytes (CD14⁺); APC anti-CD3, APC-Cy7 anti-CD4, Hoechst Blue anti-CD8, FITC anti-CD56, and isothiocyanate (FITC) anti-CD45RA, and PE anti-CD31 packaging signal and the reference gene RPP30. The cell number was calculated as one-half of the VCN, which was calculated as the number of vector copies per cell (see Data S2 for all primer/probe sequences). For Pt2, the copy number of the GCsapM-ADA vectors was also determined using ddPCR. The copy number of each integration was normalized by ddPCR. The copy number of each integration was normalized by ddPCR. The copy number of each integration was normalized by ddPCR.

IS analysis

Genomic DNA was extracted from sorted cell subsets, and the VCN was determined using the Bio-Rad QX200 ddPCR system (Bio-Rad, Hercules, CA, USA) with primers/probes directed against the vector packaging signal and the reference gene RPP30. The cell number was calculated as one-half of the RPP30-positive droplet counts, as each cell was diploid. The VCN was calculated as the number of vector copies per cell (see Data S2 for all primer/probe sequences). For Pt2, the copy number of the GCsapM-ADA vectors was also determined using primers and probe specific for the vector.

IS-specific ddPCR

Primers and probes were designed to detect the boundaries between the LTR and the host genome in high-ranked integrations identified by high-throughput sequencing (Data S2). Genomic DNA from the target cell subsets was analyzed for the presence of each integration by ddPCR. The copy number of each integration was normalized by the cell number, which was calculated as one-half of the RPP30-positive droplets.
Transcription levels of cancer-related genes proximal to ISs
RNA was extracted from the PB using the RNasy Mini Kit (QIAGEN). Transcription levels of TRAP1, GPXI, and RAP1B in P11 and DPP4, PERP, TNAFIP3, MLLT10, and SMARCCL1 in Pt2 and the reference gene TBP were analyzed using the Prime Time Std qPCR Assay (Integrated DNA Technologies, Coralville, IA, USA) and One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad), followed by the calculation of signal-positive droplets using the Bio-Rad QX200 system. The expression level of each gene was normalized relative to the expression of TBP.

ELISA assays of RANKL and OPG
An ELISA assay of RANKL and OPG was performed on plasma from patients and normal pediatric donors using Human RANKL ELISA kit and Human Osteoprotegerin ELISA kit (Abcam, Cambridge, UK) was performed on plasma from patients and normal pediatric donors according to the manufacturer’s instructions.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtm.2021.10.003.

ACKNOWLEDGMENTS
We thank both patients and their families for their cooperation. We are also grateful to the medical staff who cared for the patients. We thank the laboratory staff at the Department of Human Genetics, National Research Institute for Child Health and Development, for excellent support. This research was supported by grants from the Japan Agency for Medical Research and Development (project number 17ek0109167h0002) and National Center for Child Health and Development (grant number 28-1).

AUTHOR CONTRIBUTIONS
T.U. and M.Onodera analyzed data and wrote the manuscript. S.T. and K.E. mainly performed the genetic and cell biology experiments. K.N. and K.O. developed the system for IS analysis. N.W. and E.M. performed cell sorting. T.Y. and A.M. performed experiments. M.Y., M.K., D.T., M.Otsu, and T.A. provided technical support and conceptual advice.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Hershfield, M.S. (1998). Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 35, 291–298.
2. Gaspar, H.B., Aiuti, A., Porta, F., Candotti, F., Hershfield, M.S., and Notarangelo, L.D. (2009). How I treat ADA deficiency. Blood 114, 3524–3532.
3. Mukherjee, S., and Thrasher, A.J. (2013). Gene therapy for PID: progress, pitfalls and prospects. Gene 525, 174–181.
4. Touzet, F., Hacin-Bey-Abina, S., Fischer, A., and Cavazzana, M. (2014). Gene therapy for inherited immunodeficiency. Expert Opin. Biol. Ther. 14, 789–798.
5. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413.
6. Gaspar, H.B., Bjorkegren, E., Parsley, K., Gilmour, K.C., King, D., Sinclair, J., Zhang, F., Giannakopoulos, A., Adams, S., Fairbanks, I.D., et al. (2006). Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14, 505–513.
7. Candotti, F., Shaw, K.L., Muul, L., Carbonaro, D., Solovic, R., Choi, C., Schurman, S.H., Garabedian, E., Kesserwan, C., Jagadeesh, G.J., et al. (2012). Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120, 3635–3646.
8. Gaspar, H.B., Cooray, S., Gilmour, K.C., Parsley, K.L., Zhang, F., Adams, S., Bjorkegren, E., Bayford, J., Brown, L., Davies, E.G., et al. (2011). Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80.
9. Cooper, A.R., Lil, G.R., Shaw, K., Carbonaro-Sarracino, D.A., Davila, A., Solovic, R., Candotti, F., Pellegrini, M., and Kohn, D.B. (2017). Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients. Blood 129, 2624–2635.
10. Shaw, K.L., Garabedian, E., Mishra, S., Barman, P., Davila, A., Carbonaro, D., Shupien, S., Silvin, C., Geiger, S., Nowicki, B., et al. (2017). Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. J. Clin. Invest. 127, 1689–1699.
11. Otsu, M., Yamada, M., Nakajima, S., Kida, M., Maeyama, Y., Hatano, N., Toita, T., Takezaki, S., Okura, Y., Kobayashi, R., et al. (2015). Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. J. Clin. Immunol. 35, 384–398.
12. Igarashi, Y., Uchiyama, T., Minegishi, T., Takahashi, S., Watanabe, N., Kawai, T., Yamada, M., Ariga, T., and Onodera, M. (2017). Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy. Mol. Ther. Methods Clin. Dev. 6, 8–16.
13. Onodera, M., Ariga, T., Kawamura, N., Kobayashi, I., Ohtsu, M., Yamada, M., Tame, A., Furuita, H., Okano, M., Matsumoto, S., et al. (1998). Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91, 30–36.
14. Biasco, L., Ambrosi, A., Pellin, D., Bartholomae, C., Brugida, I., Roncarolo, M.G., Di Serio, C., van Kalle, C., Schmidt, M., and Aiuti, A. (2011). Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol. Med. 3, 89–101.
15. Matassa, D.S., Amoroso, M.R., Maddalena, F., Landriscina, M., and Esposito, F. (2012). New insights into TRAP1 pathway. Am. J. Cancer Res. 2, 235–248.
16. Masgras, I., Sanchez-Martín, C., Colombo, G., and Rosado, A. (2017). The Chaperone TRAP1 as A Modulator of the Mitochondrial Adaptations in Cancer Cells. Front. Oncol. 7, 58.
17. Zhang, J., Niu, C., Yu, L., Huang, H., He, X., Tong, W.G., Ross, J., Haug, J., Johnson, T., Feng, J.Q., et al. (2003). Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836–841.
18. Calvi, L.M., Adams, G.B., Weinbrecht, K.W., Weber, J.M., Olson, D.P., Knight, M.C., Martin, R.P., Schipani, E., Divieti, P., Brinbrug, F.R., et al. (2003). Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841–846.
19. Mansour, A., Abou-Ezzi, G., Sitnicka, E., Jacobsen, S.E., Wakkach, A., and Blin-Wakkach, C. (2012). Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J. Exp. Med. 209, 537–549.
20. Sauer, A.V., Mrak, E., Hernandez, R.J., Zacchi, E., Cavani, F., Casiraghi, M., Grunebaum, E., Roifman, C.M., Cervi, M.C., Ambrosi, A., et al. (2009). ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 114, 3216–3226.
21. Shore, A., Dosch, H.M., and Gelfand, E.W. (1981). Role of adenosine deaminase in the early stages of precursor T cell maturation. Clin. Exp. Immunol. 44, 152–155.
22. Mitchell, B.S., Mejias, E., Daddona, P.E., and Kelley, W.N. (1978). Purinergic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc. Natl. Acad. Sci. USA 75, 5011–5014.
23. Wilson, J.M., Mitchell, B.S., Daddona, P.E., and Kelley, W.N. (1979). Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. J. Clin. Invest. 64, 1475–1484.

24. Van De Wiele, C.J., Vaughan, J.G., Blackburn, M.R., Ledent, C.A., Jacobson, M., Jiang, H., and Thompson, L.F. (2002). Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J. Clin. Invest. 110, 395–402.

25. Huang, S., Apasov, S., Koshiba, M., and Sitkovsky, M. (1997). Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90, 1600–1610.

26. Foulds, K.E., Zarewicz, L.A., Shedlock, D.J., Jiang, J., Troy, A.E., and Shen, H. (2002). Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168, 1528–1532.

27. Li, C.R., Santos, S., and Lo, D.D. (2007). Quantitative analysis of T cell homeostatic proliferation. Cell. Immunol. 250, 40–54.

28. Berard, M., and Tough, D.F. (2002). Qualitative differences between naive and memory T cells. Immunology 106, 127–138.

29. Vibert, J., and Thomas-Vasin, V. (2017). Modelling T cell proliferation: Dynamics heterogeneity depending on cell differentiation, age, and genetic background. PLoS Comput. Biol. 13, e1005417.

30. Brigida, I., Sauer, A.V., Ferrua, F., Giannelli, S., Scaramuzzo, S., Pistoia, V., Castiello, M.C., Barendregt, B.H., Cicalese, M.P., Casiraghi, M., et al. (2014). B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. J. Allergy Clin. Immunol. 133, 799–806.e10.

31. Sokolic, R., Maric, I., Kesserwan, C., Garabedian, E., Hanson, I.C., Dodds, M., Buckley, R., Issekutz, A.C., Kamani, N., Shaw, K., et al. (2011). Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 118, 2688–2694.